Clinical trial · Observational
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
NCT05509855CI-TRIAL-00082750enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| T-cell Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
| T-cell Lymphoblastic Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic: WU-CART-007 | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with WU-CART-007
- description
- Patients who received previous treatment with WU-CART-007
- interventionNames
- Genetic: Genetic: WU-CART-007
Primary outcomes (3)
- measure
- Delayed adverse events (AEs)/serious adverse events (SAEs)
- timeFrame
- up to 15 years
- description
- assess the risk of delayed adverse events including serious events following exposure to WU-CART-007
- measure
- Persistence of WU-CART-007 cells
- timeFrame
- Every 6 months for up to 5 years and then yearly for up to 15 years
- description
- Peripheral blood samples will be monitored used polymerase chain reaction for persistence of WU-CART-007 cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: Patients that received WU-CART-007 in the context of any investigational study will be eligible to participate in this long-term follow-up study. Exclusion Criteria: Not Applicable
References
Publications (0)
Data not yet available
No reference posted for this study.